249 related articles for article (PubMed ID: 21765802)
21. Rescue from neonatal death in the murine model of hereditary tyrosinemia by glutathione monoethylester and vitamin C treatment.
Langlois C; Jorquera R; Orejuela D; Bergeron A; Finegold MJ; Rhead WJ; Tanguay RM
Mol Genet Metab; 2008 Mar; 93(3):306-13. PubMed ID: 18023223
[TBL] [Abstract][Full Text] [Related]
22. Cas9-nickase-mediated genome editing corrects hereditary tyrosinemia in rats.
Shao Y; Wang L; Guo N; Wang S; Yang L; Li Y; Wang M; Yin S; Han H; Zeng L; Zhang L; Hui L; Ding Q; Zhang J; Geng H; Liu M; Li D
J Biol Chem; 2018 May; 293(18):6883-6892. PubMed ID: 29507093
[TBL] [Abstract][Full Text] [Related]
23. Ex vivo hepatic gene therapy of a mouse model of Hereditary Tyrosinemia Type I.
Overturf K; Al-Dhalimy M; Manning K; Ou CN; Finegold M; Grompe M
Hum Gene Ther; 1998 Feb; 9(3):295-304. PubMed ID: 9508047
[TBL] [Abstract][Full Text] [Related]
24. Messenger RNA as a source of transposase for sleeping beauty transposon-mediated correction of hereditary tyrosinemia type I.
Wilber A; Wangensteen KJ; Chen Y; Zhuo L; Frandsen JL; Bell JB; Chen ZJ; Ekker SC; McIvor RS; Wang X
Mol Ther; 2007 Jul; 15(7):1280-7. PubMed ID: 17440442
[TBL] [Abstract][Full Text] [Related]
25. Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.
Colemonts-Vroninks H; Neuckermans J; Marcelis L; Claes P; Branson S; Casimir G; Goyens P; Martens GA; Vanhaecke T; De Kock J
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375092
[TBL] [Abstract][Full Text] [Related]
26. Sleeping Beauty transposon system is a reliable gene delivery tool for hereditary tyrosinaemia type 1 disease gene therapy: size of the foreign gene decides the timing of stable integration into the host chromosomes.
Pan XJ; Ma ZZ; Zhang QJ; Fan L; Li QH
J Int Med Res; 2012; 40(5):1850-9. PubMed ID: 23206466
[TBL] [Abstract][Full Text] [Related]
27. Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1.
Aponte JL; Sega GA; Hauser LJ; Dhar MS; Withrow CM; Carpenter DA; Rinchik EM; Culiat CT; Johnson DK
Proc Natl Acad Sci U S A; 2001 Jan; 98(2):641-5. PubMed ID: 11209059
[TBL] [Abstract][Full Text] [Related]
28. Infiltrating neutrophils aggravate metabolic liver failure in fah-deficient mice.
Qi Z; Wang X; Wei H; Sun R; Tian Z
Liver Int; 2015 Mar; 35(3):774-85. PubMed ID: 24840069
[TBL] [Abstract][Full Text] [Related]
29. Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia.
Pankowicz FP; Barzi M; Legras X; Hubert L; Mi T; Tomolonis JA; Ravishankar M; Sun Q; Yang D; Borowiak M; Sumazin P; Elsea SH; Bissig-Choisat B; Bissig KD
Nat Commun; 2016 Aug; 7():12642. PubMed ID: 27572891
[TBL] [Abstract][Full Text] [Related]
30. Homologous recombination mediates stable Fah gene integration and phenotypic correction in tyrosinaemia mouse-model.
Junge N; Yuan Q; Vu TH; Krooss S; Bednarski C; Balakrishnan A; Cathomen T; Manns MP; Baumann U; Sharma AD; Ott M
World J Hepatol; 2018 Feb; 10(2):277-286. PubMed ID: 29527263
[TBL] [Abstract][Full Text] [Related]
31. Hepatotoxicity and Toxicology of
Kaiser RA; Nicolas CT; Allen KL; Chilton JA; Du Z; Hickey RD; Lillegard JB
Hum Gene Ther Clin Dev; 2019 Jun; 30(2):57-66. PubMed ID: 30860398
[TBL] [Abstract][Full Text] [Related]
32. Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I.
Overturf K; al-Dhalimy M; Ou CN; Finegold M; Tanguay R; Lieber A; Kay M; Grompe M
Hum Gene Ther; 1997 Mar; 8(5):513-21. PubMed ID: 9095403
[TBL] [Abstract][Full Text] [Related]
33. Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1.
Ates I; Stuart C; Rathbone T; Barzi M; He G; Major AM; Shankar V; Lyman RA; Angner SS; Mackay TFC; Srinivasan S; Farris AB; Bissig KD; Cottle RN
Hepatol Commun; 2024 May; 8(5):. PubMed ID: 38668730
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report.
Grompe M; Overturf K; al-Dhalimy M; Finegold M
J Inherit Metab Dis; 1998 Aug; 21(5):518-31. PubMed ID: 9728332
[TBL] [Abstract][Full Text] [Related]
35. Efficient production of Fah-null heterozygote pigs by chimeric adeno-associated virus-mediated gene knockout and somatic cell nuclear transfer.
Hickey RD; Lillegard JB; Fisher JE; McKenzie TJ; Hofherr SE; Finegold MJ; Nyberg SL; Grompe M
Hepatology; 2011 Oct; 54(4):1351-9. PubMed ID: 21674562
[TBL] [Abstract][Full Text] [Related]
36. Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1.
Morrow G; Tanguay RM
Adv Exp Med Biol; 2017; 959():9-21. PubMed ID: 28755181
[TBL] [Abstract][Full Text] [Related]
37. Efficient liver repopulation of transplanted hepatocyte prevents cirrhosis in a rat model of hereditary tyrosinemia type I.
Zhang L; Shao Y; Li L; Tian F; Cen J; Chen X; Hu D; Zhou Y; Xie W; Zheng Y; Ji Y; Liu M; Li D; Hui L
Sci Rep; 2016 Aug; 6():31460. PubMed ID: 27510266
[TBL] [Abstract][Full Text] [Related]
38. Tyrosinemia type I and not treatment with NTBC causes slower learning and altered behavior in mice.
Hillgartner MA; Coker SB; Koenig AE; Moore ME; Barnby E; MacGregor GG
J Inherit Metab Dis; 2016 Sep; 39(5):673-682. PubMed ID: 27271696
[TBL] [Abstract][Full Text] [Related]
39. Tyrosinemia type 1: a rare and forgotten cause of reversible hypertrophic cardiomyopathy in infancy.
Mohamed S; Kambal MA; Al Jurayyan NA; Al-Nemri A; Babiker A; Hasanato R; Al-Jarallah AS
BMC Res Notes; 2013 Sep; 6():362. PubMed ID: 24016420
[TBL] [Abstract][Full Text] [Related]
40. A missense mutation (Q279R) in the fumarylacetoacetate hydrolase gene, responsible for hereditary tyrosinemia, acts as a splicing mutation.
Dreumont N; Poudrier JA; Bergeron A; Levy HL; Baklouti F; Tanguay RM
BMC Genet; 2001; 2():9. PubMed ID: 11476670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
